Skip to main content
Tags: covid | vaccine | booster | sanofi | gsk | antibody | omicron

Sanofi Says COVID Booster Shot Has Potential Against Current Omicron Variants

globe with mask, vial of covid vaccine against omicron
(Dreamstime)

Monday, 13 June 2022 08:19 AM EDT

French drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the omicron BA.1 and BA.2 strains, when used as a booster shot.

While the two companies' first experimental COVID shot is undergoing review by the European Medicines Agency, Sanofi and GSK have continued work on a vaccine that is molded on the now-supplanted beta variant, hoping still that it will confer broad protection against future viral mutations.

Sanofi said this new vaccine candidate was shown to significantly boost antibody levels against a number of variants of concern, when given to trial participants who had an initial course of mRNA vaccines, a type made by BioNTech-Pfizer and Moderna.

In a separate trial conducted by a French hospitals network, Sanofi's beta-adapted booster shot triggered a higher immune response than Sanofi's first-generation shot or Pfizer-BioNTech's established vaccine in previously vaccinated volunteers. "The beta variant expresses similar mutations across multiple variants of concern, including omicron, making it a strong vaccine candidate to confer broad protection against multiple strains of COVID-19," said Thomas Triomphe, the head of Sanofi's vaccine business.

Highlighting the need for vaccine makers to address new variants of concern in a saturated COVID vaccine market, Valneva on Friday said it was in talks to try and salvage a supply agreement that the European Commission canceled.

Valneva's product is based on the original virus found in the Chinese city of Wuhan, like BioNTech-Pfizer and Moderna's dominant first-generation shots.

© 2024 Thomson/Reuters. All rights reserved.


Health-News
French drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the omicron BA.1 and BA.2 strains.
covid, vaccine, booster, sanofi, gsk, antibody, omicron
259
2022-19-13
Monday, 13 June 2022 08:19 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Interest-Based Advertising | Do not sell or share my personal information

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved
Download the NewsmaxTV App
Get the NewsmaxTV App for iOS Get the NewsmaxTV App for Android Scan QR code to get the NewsmaxTV App
NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved